By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Nacalai USA today said that it has signed an agreement to distribute Techulon's Glycofect Transfection Reagent platform products in Japan.

The reagents are designed to be particularly effective in primary cells of therapeutic interest, said Nacalai. In addition, the San Diego-based firm said that the Glycofect family of reagents has a unique biodegradable composition that provides for efficacious delivery with very low toxicity in key cell types.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.